Department of Pathology, Galveston National Laboratory and Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA.
Publications dans "Arénavirus de l'Ancien Monde" :
Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.
CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Institut National de la Santé et de la Recherche Médicale U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5308, École Normale Supérieure de Lyon, Lyon, France.
Publications dans "Arénavirus de l'Ancien Monde" :
Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France. sylvain.baize@pasteur.fr.
CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Institut National de la Santé et de la Recherche Médicale U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5308, École Normale Supérieure de Lyon, Lyon, France. sylvain.baize@pasteur.fr.
Publications dans "Arénavirus de l'Ancien Monde" :
Department of Pathology, Galveston National Laboratory and Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA.
Publications dans "Arénavirus de l'Ancien Monde" :
Department of Pathology, Galveston National Laboratory and Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA chhuang@utmb.edu.
Publications dans "Arénavirus de l'Ancien Monde" :
Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
Publications dans "Arénavirus de l'Ancien Monde" :
Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
Publications dans "Arénavirus de l'Ancien Monde" :
Laboratory of Parasitology, Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, North 18 West 9, Kita-ku, Sapporo 060-0818, Japan.
Publications dans "Arénavirus de l'Ancien Monde" :
Department of Diseases Control, School of Veterinary Medicine, The University of Zambia, P.O. Box 32379, Lusaka 10101, Zambia.
Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
One Health Research Center, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
Publications dans "Arénavirus de l'Ancien Monde" :
Hand-foot syndrome (HFS), also known as palmoplantar erythrodysesthesia or acral erythema, is a known adverse effect of chemotherapeutic agents that most commonly presents as palmoplantar dysesthesia ...
Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment interruptions (26 %) or treatment discontinuation (17 %), and can severely decrease quality of life. In ...
Patients treated with capecitabine according to standard of care were enrolled after providing written informed consent for genotyping purposes. Prospectively collected blood samples were used to extr...
Of the 446 patients eligible for analysis, 146 (32.7 %) developed HFS, of whom 77 patients (17.3 %) experienced HFS ≥ grade 2. In the multivariable model, CES1 1165-33 C>A (rs2244613, minor allele fre...
We showed that CES1 1165-33 C>A and CDA 266 + 242 A>G are significantly associated with HFS grade 2 and grade 3 in patients treated with capecitabine. Prospective studies should assess whether this in...
This retrospective study was conducted to identify risk factors for developing hand-foot syndrome (HFS) and to determine new strategies for improving quality of life (QoL) in patients undergoing chemo...
Between April 2014 and August 2018, we enrolled 165 cancer patients at our outpatient chemotherapy center who were undergoing capecitabine chemotherapy. Variables related to the development of HFS wer...
Risk factors for the development of HFS included concomitant use of a renin-angiotensin system (RAS) inhibitor (odds ratio [OR] = 2.85, 95% confidence interval [CI] = 1.20-6.79; p = 0.018), body surfa...
Concomitant use of RAS inhibitor, high BSA, and low albumin were identified as risk factors for the development of HFS. The identification of potential risk factors of HFS may assist in the developmen...
To map topical interventions used to prevent hand-foot syndrome in cancer patients undergoing antineoplastic therapy....
This is a scoping review reported in accordance with the recommendations of PRISMA-ScR (extension for scoping review) and the Joanna Briggs Institute Manual. The searches were carried out in the elect...
The searches resulted in 12,016 references and the final sample consisted of 45 studies. A total of 42 topical interventions were identified, including: moisturizing creams, corticosteroids, acids, ma...
The results allowed reviewing topical interventions, with emphasis on the use of urea and moisturizing creams. However, most of the interventions identified in this review require evaluation in future...
To systematically evaluate the prevalence of hand-foot syndrome (HFS) in patients with colorectal cancer undergoing chemotherapy....
The PubMed, Embase, and Cochrane Library databases were searched, from their inception to September 20, 2022, to identify studies on the prevalence of HFS in patients with colorectal cancer receiving ...
A total of 20 studies were included, involving 4773 cases. Meta-analysis of the random effects model showed that the total prevalence of HFS in patients with colorectal cancer undergoing chemotherapy ...
The present findings showed that the prevalence of HFS in patients with colorectal cancer receiving chemotherapy was high. Healthcare professionals should provide knowledge to such patients regarding ...
Hand-foot syndrome (HFS) is a frequently occurring and treatment-requiring adverse effect of docetaxel. We previously reported that systemic dexamethasone (DEX) prevents the other docetaxel-induced ad...
Capecitabine-induced hand-foot syndrome (HFS) is common in clinical practice. There are many regimens used to prevent HFS. However, the most effective preventive regimen has not yet been identified. T...
Pegylated liposomal doxorubicin (PLD)-induced hand-foot syndrome (HFS) frequently lowers the quality of life of ovarian cancer patients. Wrist and ankle cooling, having a limited preventive effect, ha...
This study is a single-arm retrospective, observational study. Recurrent ovarian cancer patients were administered PLD ± bevacizumab. We retrospectively examined the efficacy of hands and feet cooling...
This study included 74 patients. The initial dose of PLD was 50 mg/m...
We demonstrated the efficacy of regional cooling and oral Dex for primary prevention of PLD-induced HFS. Although future prospective studies are needed to confirm its efficacy, this combination therap...
Fluoropyrimidines (FPs) are an essential part of the majority of systemic regimens in the treatment of metastatic colorectal cancer (CRC). The use of the oral FP S-1 has been approved by the European ...
Based on peer-reviewed published data on the use of S-1 in Western patients with metastatic CRC who switched from infusional 5-fluorouracil (5-FU) or capecitabine to S-1 for reasons of HFS or CVT, rec...
In patients who experience pain and/or functional impairment due to HFS during treatment with capecitabine or infusional 5-FU, a switch to S-1 is recommended without prior dose reduction of capecitabi...
These recommendations should guide clinicians in daily practice in the treatment of patients with metastatic CRC with FP-containing regimens....
Hand-foot syndrome (HFS) significantly impacts quality of life in cancer patients undergoing capecitabine treatment. This study assessed capecitabine-associated HFS prevalence, its impacts on chemothe...
We included adult cancer patients receiving capecitabine at Sarawak General Hospital for at least two cycles from April 1, 2021 to June 30, 2022. HFS rates, time to HFS, and proportions of HFS-related...
Among 369 patients, 185 (50.1%) developed HFS, with 14.6% experiencing grade ≥2 and 21.6% (40/185) underwent treatment modifications. Risk factors for all-grade HFS include older age (OR 1.03 95%CI 1....
This study provides real-world data on capecitabine-induced HFS in Malaysian patients and identifies risk factors that may offer insights into its understanding and management....